EA
CORT icon

Evolution Advisers’s Corcept Therapeutics CORT Stock Holding History

Evolution Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+9
New +$543 ﹤0.01% 359

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evolution Advisers's CORT Position: Q2 2026 in Review

Evolution Advisers opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 9 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #359 among its holdings.

421 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Evolution Advisers held 9 shares of Corcept Therapeutics worth $0 as of Q2 2026.
  • Corcept Therapeutics was a new Evolution Advisers position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #359 holding.
  • 421 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.